![Raffaele Colombo: AACR Annual Meeting 2024 has started!](https://oncodaily.com/pub/uploads/2024/04/Raffaele-Colombo-e1712588374409.jpg)
Raffaele Colombo: AACR Annual Meeting 2024 has started!
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on LinkedIn:
“AACR Annual Meeting 2024 has started!
It has been already a busy couple of days with a keynote lecture on ADCs at the Inaugural AACR Oncology Industry Partnering Event at AACR24.
Christiana Bardon, Michael A Caligiuri, and William N. Hait put together a fantastic event. Really enjoyed the presentations and the interactions.
On a personal level, I’m also excited to share I was recently promoted to Associate Director in Zymeworks. Thank you Jamie Rich, the senior leadership team, and whole ADC therapeutic development department!
If you are attending AACR, please stop by to our amazing ADC posters on April 8th
Morning session
1862: ZW191 – a FRa-targeting antibody drug conjugate with strong preclinical activity across multiple FRa-expressing indications (Samuel Lawn, section 22, board 6)
2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity (Stuart Barnscher, section 28, board 9)
Afternoon session
3127: Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates (Jodi Wong, section 21, board 8).
I’ll be also moderating a table discussion on ‘Careers in Biotech’, Monday evening 7-9 PM as part of PAS04 – Navigating The Path to a Successful Career in Cancer Research.
Enjoy the meeting everyone!!”
Source: Raffaele Colombo/LinkedIn